Bryan Haugen, MD

Professional Titles

• Mary Rossick Kern and Jerome H. Kern Chair in Endocrine Neoplasms Research
• Head, Division of Endocrinology

Recognitions

• Best Doctors in America, Best Doctors (2008)
  2008-2014

Research Interests

My research focuses on molecular studies of thyroid diseases and endocrine neoplasms.

Publications

• Tumor-specific Changes in Mitochondrial DNA Content in Human Cancer. Int J Cancer 116:920-924, 2005
• Novel High affinity PPAR? agonist alone and in combination with Taxol inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene, ePub, 2005
• Effects of Retinoids on Thyrotrope Function and the Hypothalamic-Pituitary-Thyroid Axis. Endocrinology 147:1438-1551, 2006
• Diagnostic Use of rhTSH versus Thyroid Hormone Withdrawal in Thyroid Carcinoma Patients Prevents a Decline in Quality of Life. J Clin Endo Metab 91:878-84, 2006
• Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, ePub Feb 2006
• Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. J Clin Endo Metab 91:926-932, 2006
• Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. J Clin Endo Metab 91:926-932, 2006
• Quantitative and Qualitative Differences in Protein Expression Between Papillary Thyroid Carcinoma and Normal Thyroid Tissue. In press, Mol Carcinogenesis
• Bauerle K, Schweppe R, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood W, Haugen B. Nuclear Factor kappa B-dependent Regulation of Angiogenesis, and Metastasis in an In Vivo Model of Thyroid Cancer is Associated with Secreted Interleukin-8. J Clin Endocrinol Metab. 2014 Apr 23;:jc20133636. [Epub ahead of print] PubMed PMID: 24758177
• Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Apr 8;:jc20141171. [Epub ahead of print] PubMed PMID: 24712572
• Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014 Mar 19;13:62. PubMed PMID: 24645981
• Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014 Jan;99(1):119-25. PubMed PMID: 24152684
• Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Kloos RT, Lanman RB, Mandel SJ, Sindy N, Steward DL, Zeiger MA, Haugen BR, Alexander EK. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med. 2013 Sep 3;159(5):325-32. PubMed PMID: 24026318
• Thyroid Neoplasms: Basic Insights and Clinical Approaches, Haugen BR (ed). Elsevier BV, Amsterdam, The Netherlands, 2005
• McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman For The National Thyroid Cancer Treatment Cooperative Study Group SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan;24(1):35-42. PubMed PMID: 23731273
• In vivo Occupancy of Transcription Factors on a TR/RXR Negatively Regulated Gene (TSH ) in a Mouse Thyrotrope Model. Endocrine Society, 2005
• Protein expression differences between follicular thyroid carcinoma and follicular thyroid adenoma. Endocrine Society, 2006
• Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb;24(2):232-40. PubMed PMID: 23721245
• Rexinoids affect TSH setpoint in thyrotropes. Endocrine Society, 2006.
• Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013 Mar 23;381(9871):1058-69. PubMed PMID: 23668556
• Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun;34(3):439-55. PubMed PMID: 23575762
• Beyond Radioiodine: Novel Therapies in Advanced Thyroid Cancer - 13th International Thyroid Congress, Buenos Aires, Argentina, 2005
• Treatment and Monitoring Strategies in Patients with Differentiated Thyroid Cancer - 7th Congress of the Portuguese Endocrine Society, Algarve, Portugal, 2006
• Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res. 2013 Mar;55(1-3):22-33. PubMed PMID: 22941561
• Thyroid Cancer: What's New in Pathogenesis, Treatment and Monitoring Strategies - 7th Annual Meeting of the American Association of Clinical Endocrinologists (Pleanry lecture), Chicago, IL, 2006
• Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong A, Kreinest P, Williams SF, Haugen BR, Klopper JP and Smallridge RC. Novel High affinity PPAR? agonist alone and in combination with Taxol inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene, 13;25(16):2304-17, 2006.
• Sharma V, Hays WR, Wood WM, Pugazhenthi U, St. Germain DL, Bianco AC, Krezel W, Chambon P and Haugen BR. Effects of Retinoids on Thyrotrope Function and the Hypothalamic-Pituitary-Thyroid Axis. Endocrinology 147:1438-1551, 2006.
• Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon III HR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC, and Ladenson PW. Diagnostic Use of rhTSH versus Thyroid Hormone Withdrawal in Thyroid Carcinoma Patients Prevents a Decline in Quality of Life. J Clin Endo Metab 91:878-84, 2006.
• Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb;24(2):232-40. PubMed PMID: 23721245
• Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109-142, 2006.
• McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman For The National Thyroid Cancer Treatment Cooperative Study Group SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan;24(1):35-42. PubMed PMID: 23731273
• Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, and Reiners C. Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. J Clin Endo Metab 91:926-932, 2006.
• Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, and Reiners C. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation after rhTSH or Hormone Withdrawal. J Nuc Med, 47:648-54, 2006.
• Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014 Jan;99(1):119-25. PubMed PMID: 24152684
• Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug;99(8):E1436-44. PubMed PMID: 24758177
• Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul;99(7):E1368-75. PubMed PMID: 24712572
• Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer, Duncan MW and Haugen BR. Quantitative and Qualitative Differences in Protein Expression Between Papillary Thyroid Carcinoma and Normal Thyroid Tissue. Mol Carcinogenesis, 45:613-26, 2006.
• Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014 Mar 19;13:62. PubMed PMID: 24645981
• Jonklass J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierly JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DR, Skarulis M, Maxon HR and Sherman SI. Outcome of patients with differentiated thyroid carcinoma following initial therapy. Thyroid, 16:1229-42, 2006.
• Golden W, Weber KB, Hernandez TL, Woodmansee WW, Sherman SI, and Haugen BR. A Randomized, Placebo-controlled, Cross-over Trial of the Effects of Bexarotene on the Hypothalamic-Pituitary-Thyroid Axis in Humans. J Clin Endo Metab, 92:124-30, 2007.
• Haugen BR. Does the metabolic activity of metastatic thyroid carcinoma correlate with prognosis? Nature Clinical Practice Endocrinology & Metabolism 2:488-9, 2006.
• Netea-Maier RT, Hunsucker SW, Brown LM, Helmke SM, Hermus A, Duncan MW, Haugen BR. Protein expression differences between follicular thyroid carcinoma and follicular thyroid adenoma. Endocrine Society, 2006.
• Olson AC, Haugen BR, Walter J, Kwak JJ, Bagrosky BM, Koo PJ. SPECT/CT and I131 therapy of brain metastases from follicular variant papillary thyroid carcinoma (FVPTC). J Clin Endocrinol Metab. 2014 Oct;99(10):3511-2. PubMed PMID: 25057877
• Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. PubMed PMID: 25427145
• Koo PJ, Klingensmith WC 3rd, Bagrosky BM, Haugen BR. SPECT/CT of metastatic struma ovarii. Clin Nucl Med. 2014 Feb;39(2):186-7. PubMed PMID: 23797234
• Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. J Clin Endocrinol Metab. 2014 Oct;99(10):3487-8. PubMed PMID: 25279569
• Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Mol Endocrinol. 2014 Oct;28(10):1587-8. PubMed PMID: 25271789
• Janssen J, Sharma V, Berenz A, Golden WM, Hernandez TL, Hays WR and Haugen BR. RXR-selective Retinoids (Rexinoids) Affect TSH ‘Setpoint’ in Thyrotropes. Endocrine Society, 2006.
• Klopper JP, Berenz A and Haugen BR. Acquired Resistance to a Rexinoid and TZD in the Anaplastic Thyroid Cancer Cell Line DRO Occurs in Part through Decreased PPAR? Expression. American Thyroid Association, 2006.
• Netea-Maier RT, Hunsucker SW, Hoevenaars B, Helmke SM, Slootweg P, Hermus A, Duncan MW, and Haugen BR. Quantitative and Qualitative Protein Expression Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma. Cancer Research 68:1572-80, 2008
• Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Bissonnette RP and Haugen BR. In Vivo and Microarray Analysis of the Treatment Effects of a Rexinoid on the Anaplastic Thyroid Carcinoma Cell Line DRO-90. Clin Cancer Res 14:589-96, 2008.
• Golden W, Weber KB, Hernandez TL, Woodmansee WW, Sherman SI, and Haugen BR. A Randomized, Placebo-controlled, Cross-over Trial of the Effects of Bexarotene on the Hypothalamic-Pituitary-Thyroid Axis in Humans. J Clin Endo Metab, 92:124-30, 2007.
• Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Endocr Rev. 2014 Oct;35(5):715-6. PubMed PMID: 25247379
• Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Endocrinology. 2014 Oct;155(10):3727-8. PubMed PMID: 25238132
• Said S and Haugen BR. Structural lesions: Solitary Thyroid Nodule. In: Clinical management of Thyroid Disease, Wondisford FE (ed). Elsevier BV, Amsterdam, The Netherlands, In press.
• Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942- 2014. Horm Cancer. 2014 Oct;5(5):263-4. PubMed PMID: 25200857
• Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Bissonnette RP and Haugen BR. In Vivo and Microarray Analysis of the Treatment Effects of a Rexinoid on the Anaplastic Thyroid Carcinoma Cell Line DRO-90. Clin Cancer Res 14:589-96, 2008.
• Netea-Maier RT, Hunsucker SW, Hoevenaars B, Helmke SM, Slootweg P, Hermus A, Duncan MW, and Haugen BR. Quantitative and Qualitative Protein Expression Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma. Cancer Research 68:1572-80, 2008.
• Albuja-Cruz MB, Pozdeyev N, Robbins S, Chandramouli R, Raeburn CD, Klopper J, Haugen BR, McIntyre R Jr. A "safe and effective" protocol for management of post-thyroidectomy hypocalcemia. Am J Surg. 2015 Dec;210(6):1162-9. PubMed PMID: 26601651
• Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC and Haugen BR. DNA Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. J Clin Endo Metab, 93:4331-41, 2008.
• Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. PubMed PMID: 26462967
• Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S and Haugen BR. Retinoid and Thiazolidinedione therapies in melanoma: An Analysis of Differential Response Based on Nuclear Hormone Receptor Expression. Molecular Cancer 8:16, 2009.
• Patel NU, McKinney K, Kreidler SM, Bieker TM, Russ P, Roberts K, Glueck DH, Albuja-Cruz M, Klopper J, Haugen BR. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. J Clin Ultrasound. 2015 Sep 24. [Epub ahead of print] PubMed PMID: 26402153
• Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL and Haugen BR. Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer. J Clin Endo Metab In Press.
• Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-?B Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One. 2015;10(8):e0134901. PubMed PMID: 26263379
• Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL and Haugen BR. Distinct Genetic Alterations in the MAPK Pathway Dictate Sensitivity of Thyroid Cancer Cells to MKK1/2 Inhibition. Thyroid, In Press.
• McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct;25(10):1097-105. PubMed PMID: 26203804
• Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular Testing for Mutations in Improving the Fine Needle Aspiration Diagnosis of Thyroid Nodules. J Clin Endo Metab In press.
• Klopper J, Haugen B. Can Calcitonin and Carcinoembryonic Antigen Doubling Times Predict Progression of Thyroid Carcinoma? Nature Clinical Practice Endocrinology & Metabolism 4:428-9, 2008.
• Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. PubMed PMID: 26171797
• Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun;6(2-3):87-99. PubMed PMID: 25800363
• Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May;25(5):563-4. PubMed PMID: 25778496
• Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC Jr, Sams SB, Haugen BR, French JD. PD-1 Tim-3 CD8 T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015 Jun;3(6):620-30. PubMed PMID: 25701326
• Said S and Haugen BR. Structural lesions: Solitary Thyroid Nodule. In: Clinical management of Thyroid Disease, Wondisford FE (ed). Elsevier BV, Amsterdam, The Netherlands, In press.
• Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri E, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S and Pacini F. Expanding Indications for recombinant Human TSH in Thyroid Cancer. Thyroid 18:687-94, 2008
• French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP and Haugen BR. Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer. J Clin Endo Metab, in press
• Hennessey JV, Malabanan AO, Haugen BR and Levy EG. Adverse Event Reporting in Patients Treated with Levothyroxine: Results of the Pharmacovigilance Task Force Survey of the American Thyroid Association, American Association of Clinical Endocrinologists and The Endocrine Society. Endocrine Practice, in press
• Michels A and Haugen BR. Malignant Struma Ovarii. J Clin Endo Metab, in press
• Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. PubMed PMID: 25427145
• Klopper JP, Sharma V, Bissonnette R and Haugen BR. Combination PPAR? and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR Research, epub, 2010
• Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A and Ladenson PW. Follow-up of Low-rsik Differentiated Thyroid Cancer patients who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal. J Clin Endo Metab 94:4171, 2009
• Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL and Tuttle RM. Revised American Thyroid Association Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19:1167-1214, 2009
• Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklass J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR and Sherman SI. Recurrence After Treatment of Micropapillary Thyroid Cancer. Thyroid 19:1043-8, 2009
• Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. Endocr Pract. 2017 Feb 22. [Epub ahead of print] PubMed PMID: 28225316
• French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2016 Oct 20. [Epub ahead of print] PubMed PMID: 27773653
• Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer. 2017 Feb 1;123(3):372-381. PubMed PMID: 27741354
• Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular Testing for Mutations in Improving the Fine Needle Aspiration Diagnosis of Thyroid Nodules. J Clin Endo Metab 94:2092-8, 2009
• Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 9;7(32):51619-51625. PubMed PMID: 27322211
• Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2016 Jul;101(7):2863-73. PubMed PMID: 27045886
• Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL and Haugen BR. Distinct Genetic Alterations in the MAPK Pathway Dictate Sensitivity of Thyroid Cancer Cells to MKK1/2 Inhibition. Thyroid 19:825-35, 2009
• Sinclair CF, Bumpous JM, Haugen BR, Chala A, Meltzer D, Miller BS, Tolley NS, Shin JJ, Woodson G, Randolph GW. Laryngeal examination in thyroid and parathyroid surgery: An American Head and Neck Society consensus statement: AHNS Consensus Statement. Head Neck. 2016 Jun;38(6):811-9. PubMed PMID: 26970554
• Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL and Haugen BR. Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer. J Clin Endo Metab 94:2199-2203, 2009
• Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S and Haugen BR. Retinoid and Thiazolidinedione therapies in melanoma: An Analysis of Differential Response Based on Nuclear Hormone Receptor Expression. Molecular Cancer 8:16, 2009
• Haugen BR and Kane MA. Approach to the Thyroid Cancer Patient with Extracervical Metastases. J Clin Endo Metab, in press
• Haugen B. Editorial: Centennial Celebration: An Interview with Dr Bryan Haugen on 100 Years of Thyroid Research. Mol Endocrinol. 2016 Jan;30(1):1-2. PubMed PMID: 26720254
• Haugen BR. Drugs that Suppress TSH or Cause Central Hypothyroidism. Best Practice & Res Clin Endo and Metab 23:793-800, 2009
• Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. PubMed PMID: 26462967
• Patel NU, McKinney K, Kreidler SM, Bieker TM, Russ P, Roberts K, Glueck DH, Albuja-Cruz M, Klopper J, Haugen BR. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. J Clin Ultrasound. 2016 Mar-Apr;44(3):143-51. PubMed PMID: 26402153
• Pozdeyev N, Gay L, Sokol ES, Hartmaier RJ, Deaver KE, Davis SN, French JD, Vanden Borre P, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018 Apr 3. [Epub ahead of print] PubMed PMID: 29615459
• Patel NU, Lind KE, McKinney K, Clark TJ, Pokharel SS, Meier JM, Stamm ER, Garg K, Haugen B. Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer. AJNR Am J Neuroradiol. 2018 Feb 15. [Epub ahead of print] PubMed PMID: 29449283
• Giordano TJ, Haugen B, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 Jan 24. [Epub ahead of print] PubMed PMID: 29373711
• French JD, Haugen BR. Thyroid cancer: CAR T cell therapy - potential in advanced thyroid cancer?. Nat Rev Endocrinol. 2018 Jan;14(1):10-11. PubMed PMID: 29170541
• French JD, Haugen BR. Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies?. J Clin Endocrinol Metab. 2017 Jul 1;102(7):2131-2132. PubMed PMID: 28899074
• Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?. Thyroid. 2017 Jun;27(6):751-756. PubMed PMID: 28463585
• Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. Endocr Pract. 2017 May;23(5):566-575. PubMed PMID: 28225316
• Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 Apr;27(4):481-483. PubMed PMID: 28114862
• French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017 Jun;5(6):469-481. PubMed PMID: 27773653
• Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer. 2017 Feb 1;123(3):372-381. PubMed PMID: 27741354
• Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC 3rd, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC Jr, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck. 2018 Dec 18. [Epub ahead of print] PubMed PMID: 30561068
• Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2018 Nov 8. [Epub ahead of print] PubMed PMID: 30419129
• McIver B, Freeman J, Shah JP, Shaha AR, Haugen B, Cohen E, Witterick IJ, Randolph GW. Summary of the Third World Congress on Thyroid Cancer. Thyroid. 2018 Nov;28(11):1401-1405. PubMed PMID: 30303467
• Deaver KE, Haugen BR, Pozdeyev N, Marshall CB. Outcomes of Bethesda categories III and IV thyroid nodules over 5 years and performance of the Afirma gene expression classifier: A single-institution study. Clin Endocrinol (Oxf). 2018 May 23. [Epub ahead of print] PubMed PMID: 29791966
• Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 Jun;28(6):739-747. PubMed PMID: 29774792
• Sawka AM, Carty SE, Haugen BR, Hennessey JV, Kopp PA, Pearce EN, Sosa JA, Tufano RP, Jonklaas J. American Thyroid Association Guidelines and Statements: Past, Present, and Future. Thyroid. 2018 Jun;28(6):692-706. PubMed PMID: 29698130
• Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. PubMed PMID: 29615459
• Patel NU, Lind KE, McKinney K, Clark TJ, Pokharel SS, Meier JM, Stamm ER, Garg K, Haugen B. Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer. AJNR Am J Neuroradiol. 2018 Apr;39(4):756-761. PubMed PMID: 29449283
• Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1277-1281. PubMed PMID: 29373711
• French JD, Haugen BR. Thyroid cancer: CAR T cell therapy - potential in advanced thyroid cancer?. Nat Rev Endocrinol. 2018 Jan;14(1):10-11. PubMed PMID: 29170541
• Sawka AM, Gagliardi AR, Haymart MR, Sturgeon C, Bernet V, Hoff K, Angelos P, Brito JP, Haugen BR, Kim B, Kopp PA, Mandel SJ, Ross DS, Samuels M, Sarne D, Sinclair C, Jonklaas J. A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines. Thyroid. 2020 Jan;30(1):25-33. PubMed PMID: 31830853
• Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 Nov 15;25(22):6883-6884. PubMed PMID: 31732665
• Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 May 15;25(10):3141-3151. PubMed PMID: 30737244
• Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 May;17(5):1036-1048. PubMed PMID: 30733375
• Mayson SE, Haugen BR. Molecular Diagnostic Evaluation of Thyroid Nodules. Endocrinol Metab Clin North Am. 2019 Mar;48(1):85-97. PubMed PMID: 30717912
• Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC 3rd, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC Jr, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck. 2019 Apr;41(4):843-856. PubMed PMID: 30561068
• Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2019 Feb 1;5(2):204-212. PubMed PMID: 30419129
• Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 Jan 15;27(2):585-597. PubMed PMID: 33097494
• Sawka AM, Alexander EK, Bianco AC, Chou R, Haugen BR, Kopp PA, Pearce EN, Ross DS, Smallridge RC, Jonklaas J. Challenges in Developing Recommendations Based on Low-Quality Evidence in Thyroid Guidelines. Thyroid. 2021 Jan;31(1):3-7. PubMed PMID: 32900277
• Sawka AM, Gagliardi AR, Haymart MR, Sturgeon C, Bernet V, Hoff K, Angelos P, Brito JP, Haugen BR, Kim B, Kopp PA, Mandel SJ, Ross DS, Samuels M, Sarne D, Sinclair C, Jonklaas J. A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines. Thyroid. 2020 Jan;30(1):25-33. PubMed PMID: 31830853
• Said S and Haugen BR. Structural lesions: Solitary Thyroid Nodule. In: Clinical management of Thyroid Disease, Wondisford FE (ed). Elsevier BV, Amsterdam, The Netherlands, 2009
• Klopper JP, Sharma V, Bissonnette R and Haugen BR. Combination PPAR? and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR Research, epub, 2010
• Michels A and Haugen BR. Malignant Struma Ovarii. J Clin Endo Metab 95:1505, 2010
• Hennessey JV, Malabanan AO, Haugen BR and Levy EG. Adverse Event Reporting in Patients Treated with Levothyroxine: Results of the Pharmacovigilance Task Force Survey of the American Thyroid Association, American Association of Clinical Endocrinologists and The Endocrine Society. Endocrine Practice, epub 2010
• Mehta V, Naraparaju A, Liao D, Davies L, Haugen BR, Kopp PA, Mandel SJ, Nikiforov YE, Ross DS, Shin JJ, Tuttle RM, Randolph GW. What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision. Thyroid. 2022 Jan 7. [Epub ahead of print] PubMed PMID: 34915744
• Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 Jan 12. [Epub ahead of print] PubMed PMID: 34641722
• Figge JJ, Gooding WE, Steward DL, Yip L, Sippel RS, Yang SP, Scheri RP, Sipos JA, Mandel SJ, Mayson SE, Burman KD, Folek JM, Haugen BR, Sosa JA, Parameswaran R, Tan WB, Nikiforov YE, Carty SE. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?. Thyroid. 2021 Nov;31(11):1673-1682. PubMed PMID: 34340592
• Mayson SE, Chan CM, Haugen BR. Tailoring the approach to radioactive iodine treatment in thyroid cancer. Endocr Relat Cancer. 2021 Sep 3;28(10):T125-T140. PubMed PMID: 34254949
• Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 Jan 15;27(2):585-597. PubMed PMID: 33097494
• Sawka AM, Alexander EK, Bianco AC, Chou R, Haugen BR, Kopp PA, Pearce EN, Ross DS, Smallridge RC, Jonklaas J. Challenges in Developing Recommendations Based on Low-Quality Evidence in Thyroid Guidelines. Thyroid. 2021 Jan;31(1):3-7. PubMed PMID: 32900277
• Jeon MJ, Haugen BR. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models. Endocrinol Metab (Seoul). 2022 Dec;37(6):830-838. PubMed PMID: 36604954
• Mehta V, Naraparaju A, Liao D, Davies L, Haugen BR, Kopp PA, Mandel SJ, Nikiforov YE, Ross DS, Shin JJ, Tuttle RM, Randolph GW. What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision. Thyroid. 2022 Apr;32(4):421-428. PubMed PMID: 34915744
• Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 Feb;32(2):153-163. PubMed PMID: 34641722
• French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP and Haugen BR. Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer. J Clin Endo Metab 95:2325-33, 2010
• Bauerle KT, Schweppe RE and Haugen BR. Inhibition of Nuclear Factor-kappa B Differentially Affects Thyroid Cancer Cell Growth, Apoptosis and Invasion. Molecular Cancer 9:117, 2010
• Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM and Haugen BR. A Rexinoid Antagonist Increases the Hypothalamic-Pituitary-Thyroid Set Point in Mice and Thyrotrope Cells. Mol Cell Endo
• Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR and Sherman SI. Radioiodine Therapy in Patients with Stage I Differentiated Thyroid Cancer (letter). Thyroid 20:1423-24, 2010
• Haugen BR and Kane MA. Approach to the Thyroid Cancer Patient with Extracervical Metastases. J Clin Endo Metab 95:987-93, 2010
• Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC Jr, Singer MC, Stack BC Jr, Wirth LJ, Wong RJ, Randolph GW. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024 Jan 11. [Epub ahead of print] PubMed PMID: 38206595
• Wahdan-Alaswad RS, Edgerton SM, Kim HM, Tan AC, Haugen BR, Liu B, Thor AD. Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer. Cell Cycle. 2023 Sep 18;:1-20. [Epub ahead of print] PubMed PMID: 37723865
• Greca A, Grau L, Arbet J, Liao LM, Sosa JA, Haugen BR, Kitahara CM. Anthropometric, dietary, and lifestyle factors and risk of advanced thyroid cancer: The NIH-AARP diet and health cohort study. Clin Endocrinol (Oxf). 2023 Dec;99(6):586-597. PubMed PMID: 37694684
• Pozdeyev N, Dighe M, Barrio M, Raeburn C, Smith H, Fisher M, Chavan S, Rafaels N, Shortt JA, Lin M, Leu MG, Clark T, Marshall C, Haugen BR, Subramanian D, Crooks K, Gignoux C, Cohen T. Thyroid Cancer Polygenic Risk Score Improves Classification of Thyroid Nodules as Benign or Malignant. J Clin Endocrinol Metab. 2024 Jan 18;109(2):402-412. PubMed PMID: 37683082
• Barrio M, Raeburn CD, McIntyre R , Jr, Albuja-Cruz M, Haugen BR, Pozdeyev N. Computer-Assisted Levothyroxine Dose Selection for the Treatment of Postoperative Hypothyroidism. Thyroid. 2023 May;33(5):547-555. PubMed PMID: 37084246
• Chiosea S, Hodak SP, Yip L, Abraham D, Baldwin C, Baloch Z, Gulec SA, Hannoush ZC, Haugen BR, Joseph L, Kargi AY, Khanafshar E, Livhits MJ, McIver B, Patel K, Patel SG, Randolph GW, Shaha AR, Sharma J, Stathatos N, van Zante A, Carty SE, Nikiforov YE, Nikiforova MN. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2999-3008. PubMed PMID: 37071871
• Haugen BR and Duncan MW. Applications of Proteomics to Thyroid Neoplasms: Are We There Yet? Thyroid 20:1051-2, 2010
• Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM and Haugen BR. A Rexinoid Antagonist Increases the Hypothalamic-Pituitary-Thyroid Set Point in Mice and Thyrotrope Cells. Mol Cell Endo 339:1-6, 2011
• Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, and Haugen BR. PPAR? Levels Determine the Growth and Invasive Capacity of Thyroid Cancer Cells. PPAR Research, epub 2011
• French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Klopper JP and Haugen BR. Programmed Death-1+ T Cells and Regulatory T Cells are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Metastatic Papillary Thyroid Cancer. In press, JCEM
• Chan CM, Pike LA, Jing X, Zhou Q, Lim DJ, Lund GS, Sharma V, Haugen BR, and Schweppe RE. Targeted inhibition of the Src kinase pathway with dasatinib blocks thyroid cancer growth and metastasis. Accepted, Clin Cancer Res
• Alexander EK, KennedyGC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB and Haugen BR. Validation of a Novel Gene Expression Classifier to Preoperatively Identify Benign Thyroid Nodules with Indeterminate FNA Cytology. In Revision, New Engl J Med
• Schweppe RE and Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology Thyroid 21:941-4, 2011
• Klopper JP and Haugen BR. Follicular Thyroid Cancer. In: Surgery of the Thyroid and Parathyroid Glands (2nd Edition), Randolph GW (ed). Elsevier/Saunders, 2011
• Klopper JP, Kane MA and Haugen BR. Anaplastic Thyroid Cancer and Miscellaneous Tumors of the Thyroid. In: The Thyroid (10th edition), Cooper DS and Braverman LE (ed), 2012
• French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Klopper JP and Haugen BR. Programmed Death-1+ T Cells and Regulatory T Cells are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Metastatic Papillary Thyroid Cancer. J Clin Endo Metab 97: E934-943, 2012
• Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. The Impact of Age and Gender on Papillary Thyroid Cancer Survival. J Clin Endo Metab 97 epub 2012
• Chan CM, Pike LA, Jing X, Zhou Q, Lim DJ, Lund GS, Sharma V, Haugen BR, and Schweppe RE. Targeted Inhibition of the Src Kinase Pathway with Dasatinib Blocks Thyroid Cancer Growth and Metastasis. Clin Cancer Res 18:3580-91, 2012
• Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB and Haugen BR. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. New Engl J Med 367:705-15, 2012
• Xing M, Haugen BR and Schlumberger M. Promises in molecular-based management of differentiated thyroid cancer. Lancet, 2013
• Haugen BR and Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocrine Reviews, 2013
• Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A and Slansky JE. Influence of immune cells on cancer: studies at the University of Colorado. Immunol Res 55:22-33, 2013
• Haugen BR. Radioactive iodine: current indications and dosing regimens. Endocrine Practice 18:604-10, 2012
• Klopper JP, Kane MA and Haugen BR. Anaplastic Thyroid Cancer and Miscellaneous Tumors of the Thyroid. In: The Thyroid (10th edition), Cooper DS and Braverman LE (ed), 2012

Professional Memberships

• American Association for Cancer Research, Member
• Endocrine Society, Member
• American College of Physicians (ACP), Fellow
• American Thyroid Association (ATA) , Member
• American Association of Clinical Endocrinologists (AACE), Member
• Association of American Physicians, Member

Practice Locations

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

UCHealth Diabetes and Endocrinology Clinic - Anschutz Medical Campus
1635 Aurora Ct
6th Floor
Aurora, CO 80045
720-848-2650

UCHealth Thyroid Cancer Multidisciplinary Clinic - Anschutz Medical Campus
1635 Aurora Court
Anschutz Outpatient Pavilion, 6th floor
Aurora, CO 80045
720-848-3299

Hospital Affiliation

• University of Colorado Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Endocrinology, Diabetes and Metabolism, Board Certification (1993)
• Internal Medicine, Board Certification

Conditions & Treatments

• Endocrine System (Hormones)
• Endocrine System (Hormones) - Endocrine Cancer (Parathyroid, Adrenal, Carcinoid)
• Endocrine System (Hormones) - Thyroid Cancer
• Endocrine System (Hormones) - Thyroid Disease